Immunogenicity of the Ad26. COV2. S Vaccine for COVID-19
KE Stephenson, M Le Gars, J Sadoff, AM de Groot… - Jama, 2021 - jamanetwork.com
Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the
Ad26. COV2. S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics,
magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune
responses. Design, Setting, and Participants Twenty-five participants were enrolled from
July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was …
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the
Ad26. COV2. S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics,
magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune
responses. Design, Setting, and Participants Twenty-five participants were enrolled from
July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was …
